PE20151079A1 - Tratamiento para artritis reumatoide - Google Patents

Tratamiento para artritis reumatoide

Info

Publication number
PE20151079A1
PE20151079A1 PE2015000350A PE2015000350A PE20151079A1 PE 20151079 A1 PE20151079 A1 PE 20151079A1 PE 2015000350 A PE2015000350 A PE 2015000350A PE 2015000350 A PE2015000350 A PE 2015000350A PE 20151079 A1 PE20151079 A1 PE 20151079A1
Authority
PE
Peru
Prior art keywords
rheumatoid arthritis
treatment
csf antibodies
mor103
dosages
Prior art date
Application number
PE2015000350A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PE20151079A1 publication Critical patent/PE20151079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a anticuerpos anti-GM-CSF utiles en el tratamiento de artritis reumatoide. Los anticuerpos anti-GM-CSF, en particular MOR103, se administran a pacientes que padecen de artritis reumatoide en dosificaciones que sean beneficas en una situacion clinica
PE2015000350A 2012-09-20 2013-09-19 Tratamiento para artritis reumatoide PE20151079A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
PE20151079A1 true PE20151079A1 (es) 2015-08-07

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000350A PE20151079A1 (es) 2012-09-20 2013-09-19 Tratamiento para artritis reumatoide

Country Status (23)

Country Link
US (3) US20150246969A1 (es)
EP (3) EP2897977A1 (es)
JP (3) JP2015533806A (es)
KR (3) KR20150056846A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CA (1) CA2884124A1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX2015003644A (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591B1 (es)
SG (2) SG11201501595YA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
MX2016002177A (es) 2013-08-30 2016-06-28 Takeda Gmbh Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
BR112016025126B1 (pt) * 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
UA126565C2 (uk) 2016-09-19 2022-11-02 Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. Антитіло до гм-ксф
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
PT3620171T (pt) * 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
AU2008232902B2 (en) * 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
EP2137325A1 (en) * 2007-04-02 2009-12-30 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
CN101657187B (zh) 2007-04-05 2012-07-18 桑多斯股份公司 稳定的水性g-csf制剂
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PL2215119T3 (pl) * 2007-11-13 2013-06-28 Evec Inc Przeciwciała monoklonalne, które wiążą się z hGM-CSF i kompozycje lecznicze je zawierające
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
JP5674677B2 (ja) * 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
KR101898982B1 (ko) 2008-12-22 2018-09-14 더 유니버시티 오브 멜버른 골관절염 치료
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
CA2760755A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
SI2341061T1 (sl) 2009-12-31 2013-12-31 Arven Ilac Sanayi Ve Ticaret A.S. Nov postopek za pripravo G-CSF-ja (granulocitne kolonije stimulirajočega faktorja)
JP5937523B2 (ja) * 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
US20140234298A1 (en) 2011-07-06 2014-08-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
JP2015533806A (ja) * 2012-09-20 2015-11-26 モルフォシス・アー・ゲー 関節リウマチの治療

Also Published As

Publication number Publication date
MX2015003644A (es) 2015-09-25
MX2021006111A (es) 2021-07-07
EP3345923A1 (en) 2018-07-11
US20180230208A1 (en) 2018-08-16
KR20220028177A (ko) 2022-03-08
EP3916013A1 (en) 2021-12-01
AU2013320261A1 (en) 2015-04-09
EA201590359A1 (ru) 2015-08-31
IN2015KN00657A (es) 2015-07-17
IL237554B (en) 2019-12-31
EA031489B1 (ru) 2019-01-31
IL237554A0 (en) 2015-04-30
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
CA2884124A1 (en) 2014-03-27
EP2897977A1 (en) 2015-07-29
US10913792B2 (en) 2021-02-09
HK1208231A1 (en) 2016-02-26
US20150246969A1 (en) 2015-09-03
DOP2015000070A (es) 2015-08-16
PH12015500591A1 (en) 2015-05-11
CN109999195A (zh) 2019-07-12
CN104995210A (zh) 2015-10-21
AU2016250388A1 (en) 2016-11-17
PH12015500591B1 (en) 2015-05-11
US20210130451A1 (en) 2021-05-06
BR112015006189A2 (pt) 2019-11-26
JP2022169709A (ja) 2022-11-09
CR20150153A (es) 2015-09-14
JP2018138551A (ja) 2018-09-06
BR112015006189B1 (pt) 2022-04-05
KR20150056846A (ko) 2015-05-27
SG10201803778PA (en) 2018-06-28
JP2015533806A (ja) 2015-11-26
MA37946B1 (fr) 2018-09-28
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
UA117228C2 (uk) 2018-07-10
CL2018000933A1 (es) 2018-07-20
AU2016250388B2 (en) 2018-07-19
CL2015000696A1 (es) 2015-10-23
MA37946A1 (fr) 2018-01-31

Similar Documents

Publication Publication Date Title
PE20151079A1 (es) Tratamiento para artritis reumatoide
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CU20150128A7 (es) Conjugados fármaco-anticuerpo
PE20150002A1 (es) Anticuerpos anti-fcrn
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
EA201400178A1 (ru) Лечение рака молочной железы
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
BR112015004499A2 (pt) métodos de administração de terapia de pirfenidona
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
MX2015014344A (es) Terapia contra el cancer.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
UY34679A (es) ?PROCEDIMIENTO PARA OBTENER UNA COMPOSICIÓN DE IgG MEDIANTE TRATAMIENTO TÉRMICO?
EA201391173A1 (ru) Изоксазолидиновые производные
CR20130065A (es) Composiciones de anticuertpo anti-vegfr-3
EA200970816A1 (ru) Новая лекарственная форма
AR089079A1 (es) Formulacion de anticuerpo anti-cd44
AR118704A2 (es) Polipéptido del factor vii para tratar enfermedades
UA74882U (uk) Фармацевтична композиція для лікування сексуальної дисфункції
NZ743656A (en) Methods of treating a tauopathy
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
UA65175U (en) Method of uranostaphyloplasty
RU2013109157A (ru) Способ увеличения скорости психомоторных реакций анксиолитиком афобазол